Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9140997 | 0.83 | DAO (0.41) | ALDH1A1DAO | |
| SCHEMBL5355039 | 0.79 | DAO (0.43) | ALDH1A1HSD17B10TDP1DAO | |
| Hydrochloric Acid SCHEMBL27687522 | 0.77 | DAO (0.42) | ALDH1A1HSD17B10TDP1DAO | |
| SCHEMBL11475698 | 0.74 | DAO (0.39) | ALDH1A1HSD17B10TDP1DAO | |
| SCHEMBL28199444 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HSD17B10TDP1 | |
| Hydrochloric Acid SCHEMBL31601091 | 0.74 | DAO (0.35) | DAO | |
| SCHEMBL5361085 | 0.74 | CA12 (0.48) | ALDH1A1DAO | |
| SCHEMBL23569862 | 0.71 | S100A9 (0.35) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL15881245 | 0.71 | CA2 (0.54) | — | |
| SCHEMBL15880882 | 0.71 | CA2 (0.39) | ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0340472-B1 | PROCESS FOR THE PREPARATION OF 5-CHLORO-3-CHLOROSULPHONYL-2-THIOPHENE-CARBOXYLIC ESTERS | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1993-07-28 | — | — | EP | claimed |
| EP-4573088-A1 | HETEROCYCLE RBM39 MODULATORS | Recursion Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025108986-A1 | 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2025-05-30 | — | — | WO | disclosed |
| CN-119630658-A | Heterocyclic RBM39 modulators | 递归医药公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | Oxford Drug Design Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| CN-114846000-B | 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof | 牛津药物设计有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | RECURSION PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024039689-A1 | HETEROCYCLE RBM39 MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11697658-B2 | Method for preparing lornoxicam | Beijing Jincheng Taier Pharmaceutical Co., Ltd. (CN) | 2023-07-11 | — | — | US | disclosed |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2023-04-13 | — | — | US | disclosed |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| CN-101151261-A | Pyrimidine compounds having tie2 (TEK) inhibitory activity | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | CN | disclosed |
| US-7074820-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| CN-1699372-A | Process for synthesizing lornoxicam intermediate against inflammation and pain | UNIV JIANGSU POLYTECHNIC (CN) | 2005-11-23 | — | — | CN | disclosed |
| EP-0917528-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | ANTONSSON THOMAS (SE) | 2002-04-04 | — | — | US | disclosed |
| US-6221898-B1 | ANTICOAGULANTS | ASTRA AKTIEBOLAG (SE) | 2001-04-24 | — | — | US | disclosed |
| CN-1228765-A | New amidino derivatives and their use as thrombin inhibitors | ASTRA AB (SE) | 1999-09-15 | — | — | CN | disclosed |
| EP-0917528-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998001422-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247004-B2 | 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use | AARS1, ASNS, GARS1 | ALDH1A1 2000/4885HSD17B10 1697/4885TDP1 2429/4885 |
| US-20080146599-A1 | Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity | TIE1, TEK, KDR | ALDH1A1 1838/4885HSD17B10 4780/4885TDP1 1626/4885 |
| US-11697658-B2 | Method for preparing lornoxicam | KMO, HTR6, CHRM5 | ALDH1A1 1290/4885HSD17B10 3912/4885TDP1 408/4885 |
| US-20020040043-A1 | Amidino derivatives and their use as thrombin inhibitors | SERPINC1, F2, SERPINE1 | ALDH1A1 4316/4885HSD17B10 1471/4885TDP1 607/4885 |
| US-20230114875-A1 | 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | AARS1, ASNS, GARS1 | ALDH1A1 2000/4885HSD17B10 1697/4885TDP1 2429/4885 |
| US-20240092770-A1 | Heterocycle RMB39 Modulators | PRMT9, RCC2, RBBP9 | ALDH1A1 3570/4885HSD17B10 1115/4885TDP1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.